Table 4.

Sustained Virologic Response Rates (95% Confidence Intervals) in Patients infected with HCV Genotype 2, 4, and 6

	Genotype 2 SVR, % (95% CI)			Genotype 4 SVR, % (95% CI)			Genotype 6 SVR, % (95% CI)
	All patients	DAC + SOF	SOF/VEL	All patients	LDV/SOF	DAC + SOF	All patients	LDV/SOF	DAC + SOF	SOF/VEL
Patients who complete, N	14	10	4	11	1	10	152	36	109	7
All durations	100 (78.5–100)	100 (72.2–100)	100 (51.0–100)	90.9 (62.3–98.4)	100 (20.7–100)	90.0 (59.6–98.2)	96.7 (92.5–98.6)	97.2 (85.8–99.5)	96.3 (90.9–98.6)	100 (64.6–100)
12-wk treatment	100 (77.2–100)	100 (70.1–100)	100 (51.0–100)	87.5 (52.9–97.8)	100 (20.7–100)	85.7 (48.7–97.4)	97.1 (92.9–98.9)	97.0 (84.7–99.5)	97.0 (91.5–99.0)	100 (64.6–100)
16-wk treatment	NA	NA	NA	NA	NA	NA	100 (34.2–100)	NA	100 (34.2–100)	NA
24-wk treatment	100 (20.7–100)	100 (20.7–100)	NA	100 (43.9–100)	NA	100 (43.9–100)	90.0 (59.6–98.2)	100 (43.9–100)	85.7 (48.7–97.4)	NA
SVR in the following subgroups
No cirrhosis	100 (74.1–100)	100 (64.6–100)	100 (51.0–100)	100 (61.0–100)	100 (20.7–100)	100 (56.6–100)	96.8 (90.9–98.9)	100 (82.4–100)	95.8 (88.5–98.6)	100 (43.9–100)
Cirrhosis	100 (43.9–100)	100 (43.9–100)	NA	80.0 (37.6–96.4)	NA	80.0 (37.6–96.4)	96.6 (88.5–99.1)	94.4 (74.2–99.0)	97.3 (86.2–99.5)	100 (51.0–100)
Decompensated cirrhosis	100 (20.7–100)	100 (20.7–100)	NA	100 (20.7–100)	NA	100 (20.7–100)	100 (67.6–100)	100 (34.2–100)	100 (56.6–100)	100 (20.7–100)
Treatment-naive	100 (75.8–100)	100 (67.6–100)	100 (51.0–100)	83.3 (43.6–97.0)	NA	83.3 (43.6–97.0)	99.1 (94.8–99.8)	100 (88.6–100)	98.6 (92.3–99.7)	100 (61.0–100)
Treatment-experienced	100 (34.2–100)	100 (34.2–100)	NA	100 (56.6–100)	100 (20.7–100)	100 (51.0–100)	91.3 (79.7–96.6)	83.3 (43.6–97.0)	92.3 (79.7–97.3)	100 (20.7–100)